Home » Semaphore launches human testing of cancer drug

Semaphore launches human testing of cancer drug

| IBJ Staff

Phase 1 clinical trials have been started at Indiana University and a site in Arizona of Semaphore Pharmaceuticals Inc.’s cancer tumor drug.

The Indianapolis company has seen success in animal trials in an array of tumors. Semaphore’s P13K inhibitor targets the “master switch” that signals cancer cells to grow.

Please enable JavaScript to view this content.

Story Continues Below

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our updated comment policy that will govern how comments are moderated.